Anjay Rastogi, MD
Nephrology · Los Angeles, CANPI 1003836602
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,395,964 of the $2,164,559 with a category attached, or 64.5%. It is spread thinly across 40 manufacturers, the largest accounting for just 20.6%. Among nephrology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,741 payments — averaging $789.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$446K
- Bayer$275K
- Fresenius USA Marketing, Inc.$265K
- Sanofi$189K
- Vifor Pharma, Inc.$141K
- Otsuka America Pharmaceutical, Inc.$137K
- plus $712K from 34 others
Across 350 payments — averaging $11,893 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$1.2M
- Kadmon Corporation LLC$768K
- Novartis$607K
- Sanofi$431K
- AstraZeneca$413K
- Bayer$285K
- plus $427K from 9 others
What the payments were for
- Consulting fees$321,37315%
- Speaking & faculty fees$1,395,96464%
- Travel & lodging$335,97816%
- Food & beverage$74,0703%
- Education$37,1292%
- Entertainment$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LOKELMA$298,000
- Kerendia$272,474
- Velphoro$220,550
- FABRAZYME$153,627
- Parsabiv$112,026
- JARDIANCE$103,373
- JYNARQUE$90,233
- FARXIGA$86,374
- Renal - PD$73,245
- Veltassa$71,349
- Vafseo$43,991
- JESDUVROQ$37,586
- Korsuva$31,778
- Filspari$29,187
- Fabhalta$20,283
- BENLYSTA$18,356
- Tavneos$10,563
- Renal - Chronic$9,389
- TOLVAPTAN$8,805
- DISEASE STATE$8,728
How this compares
$2,164,559 in reported general payments places this provider in the 95th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Los Angeles
- Suphamai BunnapradistLos Angeles$498K
- Mohammad KamgarLos Angeles$497K
- Victor CarabelloLos Angeles$363K
- Tariq ShahLos Angeles$351K
- Susanne NicholasLos Angeles$146K
- Arishia GhaffariLos Angeles$142K
- Allen NissensonLos Angeles$101K
- Niloofar NobakhtLos Angeles$97K
- Farid ArmanLos Angeles$69K
- Glenn ChertowStanford$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.